satraplatin

Small moleculeexperimental

Satraplatin is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously. — Wikipedia

Clinical trial activity

17 trials · 19 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
8
Phase 3
2
Phase 4
0

Earliest trial started Sep 1, 2003 (NCT00069745)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

Chemistry & pharmacology

Mol. weight
500.28 g/mol
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bis-acetatoamminedichlorocyclohexylamine platinum(iv)
  • bms 182751
  • bmy 45594
  • cabazitaxel, docetaxel, mitoxantrone or satraplatin
  • jm216
  • jm216
  • jm 216
  • jm-216
  • platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)-
  • satraplatin
  • satraplatin
  • satraplatin
  • satraplatin
  • satraplatin
  • satraplatin
  • trans,cis,cis-bis(acetato)amminecyclohexylaminedichloroplatinum(iv)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03258320Phase 1Jan 31, 2015Fudan University, Jiao Tong University, Shandong University
NCT01259479Phase 1Dec 3, 2010National Cancer Institute (NCI)
NCT01289067Phase 2Dec 1, 2010Icahn School of Medicine at Mount Sinai, Prostate Cancer Foundation
NCT00634647Phase 2Feb 1, 2008National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT01220284Phase 1Feb 1, 2008Agennix, Pierre Fabre, Southern Europe New Drug Organization (SENDO), Swiss Group for Clinical Cancer Research
NCT00499694N/AOct 1, 2007National Cancer Institute (NCI), Wayne State University
NCT00480623Phase 1May 1, 2007Agennix, University of Michigan
NCT00473720Phase 1May 1, 2007Agennix, Yale University
NCT00125411Phase 1Mar 1, 2007Agennix, University of Wisconsin
NCT00450970Phase 3Feb 1, 2007Agennix, GPC Biotech Inc.
NCT00370383Phase 2Jul 1, 2006Agennix, Temple University
NCT00329329Phase 1May 1, 2006Agennix, Northwestern University
NCT00313456Phase 1Mar 1, 2006Agennix, GPC Biotech Inc.
NCT00268970Phase 2Dec 1, 2005Agennix
NCT00265655Phase 2Nov 1, 2005Agennix, US Oncology
NCT00093132Phase 1/Phase 2 (Phase 2)Aug 1, 2004Agennix
NCT00069745Phase 3Sep 1, 2003Agennix
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AgennixFor profit121032003
National Cancer Institute (NCI)Government3232007
GPC Biotech Inc.For profit2022006
Fudan UniversityAcademic/Hospital1012015
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112010
Jiao Tong UniversityAcademic/Hospital1112015
National Institutes of Health (NIH)Government1012008
Northwestern UniversityAcademic/Hospital1012006
Pierre FabreFor profit1012008
Prostate Cancer FoundationAcademic/Hospital1012010
Shandong UniversityAcademic/Hospital1012015
Southern Europe New Drug Organization (SENDO)Academic/Hospital1112008
Swiss Group for Clinical Cancer ResearchAcademic/Hospital1012008
Temple UniversityAcademic/Hospital1012006
University of MichiganAcademic/Hospital1012007
University of WisconsinAcademic/Hospital1012007
US OncologyFor profit1012005
Wayne State UniversityAcademic/Hospital1112007
Yale UniversityAcademic/Hospital1112007
19 organizations
Page 1 / 1